Rezera
Rezera develops oral experimental medicines that inhibit NLRP3, a protein involved in inflammation, for potential cardiovascular and neurological diseases.
Rezera (Ticker: RZRA US) develops oral experimental medicines that block NLRP3, a protein involved in inflammation. The company aims to reduce inflammation by acting on this pathway, with the goal of modifying cardiovascular and neurological diseases. Its lead candidate, ruvonoflast, has completed Phase 2 trials and is planned for a Phase 3 trial in peripheral artery disease in the first half of 2027, with a readout expected in 2028.
Rezera expects to begin trading on Nasdaq on November 12, 2026. The proposed offering comprises 16,666,667 shares at an indicative price of $11.00–$13.00 per share. At the $12.00 indicative midpoint, the base offering would represent approximately $200.00 million in gross proceeds.
The company’s earlier-stage candidate, trabzanoflast, has completed a Phase 1 trial, and Rezera plans to advance it to a Phase 2 proof-of-concept trial. For the six months ended June 30, 2026, Rezera reported a net loss of $25.50 million. Joint bookrunners are Jefferies, TD Cowen and Cantor.
Prepared with IPOX® AI assistance. Information may contain errors.
Prepared with IPOX® AI assistance. Information may contain errors.